Member Info for Laura2022

I don't need to, WG and "the market " have provided them since the apparent 35p deal

The market doesn't lie

How much have you stake and at what price?

That may help explain your degree of objectivity

The facts and presented in the most recent RNSs

Let's revisit this thread after suspension

My basis is based on the facts presented and the enviable position of absorbing the known knowns but also the likely curve balls

Something doesn't feel right

Best wishes

I certainly think it's nerve wracking holding past the 29th April

Net assets nearly x 4 current market value

From.most recent inteirms

The Group continues to have a strong balance sheet, with net assets of £899.6m (FY23: £987.3m) at 30 September 2024. 

With 599 posts.on WG maybe you're lacking some objectivity.?

No, is your 22.19pm?

Opinions no?

Personally would rather be out of it and safe

And from new PYCrecruit Mark Davies

Mark Davies

5h

I've seen quite a few comments and articles regarding the recent FDA announcement for phasing out animal testing requirement for mAbs, both for and against. What I think (and hope) can now happen is a systematic, data driven assessment for when different methods (whether that is in-silico, in-vitro or in-vivo) can be applied and what we should expe

Physiomics plc

1,854 followers

6h Edited

Many in the MIDD space will recognise the iconic René Magritte painting this image pays homage to. 👇 The point, of course, is to challenge perception: the original painting of a pipe doesn't make it a pipe – but if it helps us understand what a pipe is, it serves a purpose.

The same goes for the tools we use in drug development.

Mouse models are not human beings. They've historically helped us gain insights into how drugs might behave. But if, in certain scenarios, they’re no longer helping us understand what would happen in a human, they’re no longer useful - and should be replaced.

To be fair, mathematical models aren’t human beings either. But – along with more physiological in-vitro tests – they allow us to analyse the totality of evidence (including real-world data) to generate deeper insight into how drugs, like monoclonal antibodies, will behave in the body. And they do this with greater transparency, lower cost, and no need for animal use.

For drug developers and regulators, that’s where their value lies.

At Physiomics plc, we’re optimistic about the recent FDA announcement encouraging the phase out of animal testing requirements for monoclonal antibodies and other drugs. 👇 The more we challenge what’s useful – and what’s not – the better we become at advancing smarter, safer, more ethical drug development.

🧪 What’s your take on the FDA’s latest announcement? Drop your thoughts in the comments. 💬

Falcon

I sold for good profit in the 30s

I've been watching ever since (see my posts )

Buy backs seems to be the most common way for FTSE companies last 6mths

Accrod9ng to LSE at close:

PE Ratio 5.01

Earnings12.80

Dividend12.25

Yield19.081%

Thanks for that Rly

Further to my posts at weekend.. this is getting too close to 30th

Gluck if in, hope the 35p offer comes

Thanks TargetP

Implied dividend (if kept) is 18%

I've not bought yet though

Fonzi

I did the same to at least 2 last night

It was all clear for those with open eyes what potential lay here

I simply filtered or ignored the others

CHP PYC will be going on huge re rates in A.I sector